Blar i NTNU Open på forfatter "Zweegman, Sonja"
-
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
Misund, Kristine; Hofste op Bruinink, Davine; Coward, Eivind; Hoogenboezem, Remco M.; Rustad, Even Holth; Sanders, Mathijs A.; Rye, Morten Beck; Sponaas, Anne-Marit; van der Holt, Bronno; Zweegman, Sonja; Hovig, Eivind; Meza, Leonardo Zepeda; Sundan, Anders; Myklebost, Ola; Sonneveld, Pieter; Waage, Anders (Peer reviewed; Journal article, 2022)We investigated genomic and transcriptomic changes in paired tumor samples of 29 in-house multiple myeloma (MM) patients and 28 patients from the MMRF CoMMpass study before and after treatment. A change in clonal composition ... -
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study
Nielsen, Lene Kongsgaard; Stege, Claudia; Lissenberg-Witte, Birgit I.; van der Holt, Bronno; Mellqvist, Ulf-Henrik; Salomo, Morten; Bos, Gerard; Levin, Mark-David; Visser-Wisselaar, Heleen; Hansson, Markus; van der Velden, Annette W.G.; Deenik, Wendy; Coenen, Juleon; Hinge, Maja; Klein, Saskia K.; Tanis, Bea C.; Szatkowski, Damian Lukasz; Brouwer, Rolf E.; Westerman, Matthijs; Leys, Rineke; Sinnige, Harm A.M.; Haukås, Einar; van der Hem, Klaas G.; Durian, Marc F.; Gimsing, Peter; van de Donk, Niels; Sonneveld, Pieter; Waage, Anders; Abildgaard, Niels; Zweegman, Sonja (Peer reviewed; Journal article, 2019)Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ... -
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials
Palumbo, Antonio; Waage, Anders; Hulin, Cyrille; Beksac, M; Zweegman, Sonja; Gay, Francesca; Gimsing, Peter; Leleu, X; Wijermans, P; Sucak, G; Pezzatti, S; Juliusson, Gunnar; Pegourie, B; Schaafsma, Marije; Galli, M; Turesson, Ingemar; Kolb, B; van der Holt, B; Baldi, I; Rolke, Jürgen; Ciccone, G; Wetterwald, M; Lokhorst, H; Boccadoro, Mario; Rodon, P; Sonneveld, Pieter (Journal article; Peer reviewed, 2013)Treatment with melphalan-prednisone-thalidomide improves the outcome of patients with multiple myeloma and is now considered a standard of care for patients not eligible for transplantation. However, this treatment is a ... -
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: Recommendations from the European Myeloma Network
van de Donk, Niels W.C.J.; Palumbo, Antonio; Johnsen, Hans Erik; Engelhardt, Monika; Gay, Francesca; Gregersen, Henrik; Hájek, Roman; Kleber, Martina; Ludwig, Heinz; Morgan, Gareth; Musto, Pellegrino; Plesner, Torben; Sezer, Orhan; Terpos, Evangelos; Waage, Anders; Zweegman, Sonja; Einsele, Hermann; Sonneveld, Pieter; Lokhorst, Henk (Journal article; Peer reviewed, 2014)Monoclonal gammopathy of undetermined significance is one of the most common pre-malignant disorders. IgG and IgA monoclonal gammopathy of undetermined significance are precursor conditions of multiple myeloma; light-chain ...